Drugs / OCS-01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05608837 | May 2023 → Jun 2026 overdue | cystoid macular edema | Quan Dong Nguyen | Active not recruiting | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05147233 | Jun 2022 → Jun 2023 | cataract, eye adnexa disorder | Oculis | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-29 | Oculis | Results Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema oculis.com ↗
The primary endpoint, mean change in best corrected visual acuity early treatment diabetic retinopathy study (BCVA ETDRS) letter score at Week 52, was not met in both trials. |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OCS-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05608837 ↗ |
| Known as | Dexamethasone | “1 drop of OCS-01 (Dexamethasone ophthalmic suspension 1.5%” NCT05147233 ↗ |
| Modality | Small molecule | “a new kind of steroid eye drops, OCS-01” NCT05608837 ↗ |
| Route | Topical | “OCS-01 Eyedrops” NCT05147233 ↗ |